Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2010
Assuntos:
Commentary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2917408/
https://ncbi.nlm.nih.gov/pubmed/20630094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-67
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados